Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002716819 | SCV003001232 | uncertain significance | Jeune thoracic dystrophy; Nephronophthisis | 2023-06-29 | criteria provided, single submitter | clinical testing | This variant has not been reported in the literature in individuals affected with TTC21B-related conditions. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on TTC21B protein function. ClinVar contains an entry for this variant (Variation ID: 1966772). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces tyrosine, which is neutral and polar, with aspartic acid, which is acidic and polar, at codon 18 of the TTC21B protein (p.Tyr18Asp). |
Ambry Genetics | RCV003269260 | SCV003982792 | uncertain significance | Inborn genetic diseases | 2023-05-18 | criteria provided, single submitter | clinical testing | The c.52T>G (p.Y18D) alteration is located in exon 2 (coding exon 2) of the TTC21B gene. This alteration results from a T to G substitution at nucleotide position 52, causing the tyrosine (Y) at amino acid position 18 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV005027928 | SCV005653398 | uncertain significance | Asphyxiating thoracic dystrophy 4; Nephronophthisis 12 | 2024-04-23 | criteria provided, single submitter | clinical testing |